Seregni E - Search Results

1

Pilot, multicenter and prospective trials with an anti-CEA antibody.

Buraggi GL, Gasparini M, Seregni E, Bombardieri E, Regalia E, Maffioli L. Buraggi GL, et al. Among authors: seregni e. Int J Biol Markers. 1992 Jul-Sep;7(3):189-92. doi: 10.1177/172460089200700312. Int J Biol Markers. 1992. PMID: 1431344 Clinical Trial.

2

The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan.

Seregni E, Bombardieri E, Bogni A, Crippa F, De Jager E, Buraggi GL. Seregni E, et al. Int J Biol Markers. 1992 Jul-Sep;7(3):167-70. doi: 10.1177/172460089200700308. Int J Biol Markers. 1992. PMID: 1431340

3

CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastases.

Bombardieri E, Pizzichetta M, Veronesi P, Seregni E, Bogni A, Maffioli L, Jotti GS, Bassetto MA, Zurrida S, Costa A. Bombardieri E, et al. Among authors: seregni e. Eur J Cancer. 1992;29A(1):144-6. doi: 10.1016/0959-8049(93)90595-7. Eur J Cancer. 1992. PMID: 1445733

4

Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer.

Crippa F, Bombardieri E, Seregni E, Castellani MR, Gasparini M, Maffioli L, Pizzichetta M, Buraggi GL. Crippa F, et al. Among authors: seregni e. J Nucl Biol Med (1991). 1992 Jan-Mar;36(1):52-5. J Nucl Biol Med (1991). 1992. PMID: 1450226

5

CA 15.3 as a signal of undetectable breast cancer metastases in a follow-up period of 4 years.

Pizzichetta M, Bogni A, Seregni E, Maffioli L, de Jager E, Costa A, Bombardieri E. Pizzichetta M, et al. Among authors: seregni e. Int J Biol Markers. 1992 Jan-Mar;7(1):59-60. doi: 10.1177/172460089200700109. Int J Biol Markers. 1992. PMID: 1583349 No abstract available.

6

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody.

Crippa F, Buraggi GL, Di Re E, Gasparini M, Seregni E, Canevari S, Gadina M, Presti M, Marini A, Seccamani E. Crippa F, et al. Among authors: seregni e. Eur J Cancer. 1991;27(6):724-9. doi: 10.1016/0277-5379(91)90174-c. Eur J Cancer. 1991. PMID: 1829912

7

Preliminary study on serum levels of mucinous like cancer antigen (MCA) in patients with breast disease: comparison with CEA.

Boccardo F, Bombardieri E, Zanardi S, Valenti G, Zanaboni F, Valtolina M, Seregni E, Crippa F. Boccardo F, et al. Among authors: seregni e. Int J Biol Markers. 1991 Jan-Mar;6(1):12-20. doi: 10.1177/172460089100600103. Int J Biol Markers. 1991. PMID: 1856512

8

Immunoscintigraphy of colorectal carcinoma with an anti-CEA monoclonal antibody: a critical review.

Buraggi GL, Gasparini M, Seregni E. Buraggi GL, et al. Among authors: seregni e. Int J Rad Appl Instrum B. 1991;18(1):45-50. doi: 10.1016/0883-2897(91)90045-m. Int J Rad Appl Instrum B. 1991. PMID: 2010305 Review.

9

Mucinic tumor markers recognized by monoclonal antibodies.

Seregni E, Bombardieri E, Maffioli L, Buraggi GL. Seregni E, et al. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4):314-20. J Nucl Med Allied Sci. 1990. PMID: 2090797 Review. No abstract available.

10

Alpha-fetoprotein (AFP) in germ cell tumors of the testis.

Seregni E, Savelli G, Bombardieri E. Seregni E, et al. J Nucl Med Allied Sci. 1989 Jul-Sep;33(3 Suppl):42-5. J Nucl Med Allied Sci. 1989. PMID: 2480421 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

213 results

Search Page

Filters